Publication:
Impact of rheumatoid arthritis in Turkey: A questionnaire study

dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentRomatoloji Ana Bilim Dalı
dc.contributor.scopusid6506739457
dc.date.accessioned2024-01-30T10:47:31Z
dc.date.available2024-01-30T10:47:31Z
dc.date.issued2014-07
dc.descriptionÇalışmada 33 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.
dc.description.abstractObjective Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study.
dc.identifier.citationDireskeneli, H. vd. (2014). "Impact of rheumatoid arthritis in Turkey: A questionnaire study". Clinical and Experimental Rheumatology, 32(4), 653-657.
dc.identifier.endpage483
dc.identifier.issn0392-856X
dc.identifier.issue4
dc.identifier.pubmed24960289
dc.identifier.scopus2-s2.0-84904903828
dc.identifier.startpage477
dc.identifier.urihttps://hdl.handle.net/11452/39391
dc.identifier.volume32
dc.identifier.wos000341171000006
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherClinical & Exper Rheumatology
dc.relation.journalClinical and Experimental Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPatient survey
dc.subjectRheumatoid arthritis
dc.subjectQuality of life
dc.subjectTreatment algorithm
dc.subjectTherapy
dc.subjectCare
dc.subjectBiologics
dc.subjectRegistry
dc.subjectOutcomes
dc.subjectRheumatology
dc.subject.emtreeAcupuncture
dc.subject.emtreeAdult
dc.subject.emtreeAlternative medicine
dc.subject.emtreeArticle
dc.subject.emtreeBiological therapy
dc.subject.emtreeCommunication skill
dc.subject.emtreeControlled study
dc.subject.emtreeDas28
dc.subject.emtreeDoctor patient relation
dc.subject.emtreeFemale
dc.subject.emtreeHealth status
dc.subject.emtreeHealth survey
dc.subject.emtreeHuman
dc.subject.emtreeHuman impact (environment)
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMedical specialist
dc.subject.emtreePatient preference
dc.subject.emtreePhysiotherapy
dc.subject.emtreePriority journal
dc.subject.emtreeQuality of life
dc.subject.emtreeQuestionnaire
dc.subject.emtreeRehabilitation
dc.subject.emtreeRheumatoid arthritis
dc.subject.emtreeRheumatology
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeAdalimumab
dc.subject.emtreeCorticosteroid
dc.subject.emtreeEtanercept
dc.subject.emtreeInfliximab
dc.subject.emtreeLeflunomide
dc.subject.emtreeMethotrexate
dc.subject.emtreeNonsteroid antiinflammatory agent
dc.subject.meshAdult
dc.subject.meshAntirheumatic agents
dc.subject.meshArthritis, rheumatoid
dc.subject.meshAttitude of health personnel
dc.subject.meshBiological products
dc.subject.meshCommunication
dc.subject.meshDrug administration schedule
dc.subject.meshFemale
dc.subject.meshHealth care surveys
dc.subject.meshHealth knowledge, attitudes, practice
dc.subject.meshHealth services needs and demand
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshNeeds assessment
dc.subject.meshPatient preference
dc.subject.meshPatient satisfaction
dc.subject.meshPatients
dc.subject.meshPerception
dc.subject.meshPhysician-patient relations
dc.subject.meshQuality of life
dc.subject.meshQuestionnaires
dc.subject.meshSeverity of illness index
dc.subject.meshTime factors
dc.subject.meshTreatment outcome
dc.subject.meshTurkey
dc.subject.scopusGolimumab; Abatacept; Biological Products
dc.subject.wosRheumatology
dc.titleImpact of rheumatoid arthritis in Turkey: A questionnaire study
dc.typeArticle
dc.wos.quartileQ2 (Rheumatology)
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Romatoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: